Romidepsin Suppresses ESCC Cell Proliferation and Progression via HDAC2-H3K14ac-p53 Pathway

Abstract Histone deacetylase 2 (HDAC2) may contribute to epigenetic dysregulation in esophageal squamous cell carcinoma (ESCC) by silencing tumor suppressor genes, yet isoform-specific therapeutic targeting remains underexplored. Here, we show that romidepsin, an FDA-approved class I HDAC inhibitor, preferentially inhibits HDAC2-associated deacetylation in ESCC cells. We identified romidepsin as a potent inhibitor of ESCC cell viability, through phenotypic screening of 773 epigenetic compounds across differentiation-stage-defined ESCC models. Multi-omics analyses (SILAC proteomics, CUT&Tag chromatin mapping, and RNA-seq) further revealed histone H3K14ac enrichment at promoters of p53 pathway targets, including CDKN1A/p21, which exhibited transcriptional reactivation. Similar to HDAC2 knockout, romidepsin suppressed ESCC proliferation, migration, and clonogenicity. Mechanistically, HDAC2 inhibition reverses epigenetic silencing of p21 and restores tumor-suppressive chromatin states. Together, these results identify the HDAC2–H3K14ac axis as a therapeutic vulnerability in ESCC and provide preclinical support for romidepsin-based epigenetic intervention.

Authors

Institutions

Publication Details

Journal
Genomics Proteomics & Bioinformatics
Published
2026-11-14
DOI
https://doi.org/10.1093/gpbjnl/qzag112
Primary Topic
Histone Deacetylase Inhibitors Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Romidepsin Suppresses ESCC Cell Proliferation and Progression via HDAC2-H3K14ac-p53 Pathway

Chen Chen, 章馨允, Yanpu Han, Kai Zhang et al.
Genomics Proteomics & Bioinformatics
Histone Deacetylase Inhibitors Research
article

Romidepsin Suppresses ESCC Cell Proliferation and Progression via HDAC2-H3K14ac-p53 Pathway

Chen Chen, 章馨允, Yanpu Han, Kai Zhang, Xinfeng Zhou, Jianji Zhang, Yong Zang, Jianan Wang, Xue Bai
article en

Abstract

Abstract Histone deacetylase 2 (HDAC2) may contribute to epigenetic dysregulation in esophageal squamous cell carcinoma (ESCC) by silencing tumor suppressor genes, yet isoform-specific therapeutic targeting remains underexplored. Here, we show that romidepsin, an FDA-approved class I HDAC inhibitor, preferentially inhibits HDAC2-associated deacetylation in ESCC cells. We identified romidepsin as a potent inhibitor of ESCC cell viability, through phenotypic screening of 773 epigenetic compounds across differentiation-stage-defined ESCC models. Multi-omics analyses (SILAC proteomics, CUT&Tag chromatin mapping, and RNA-seq) further revealed histone H3K14ac enrichment at promoters of p53 pathway targets, including CDKN1A/p21, which exhibited transcriptional reactivation. Similar to HDAC2 knockout, romidepsin suppressed ESCC proliferation, migration, and clonogenicity. Mechanistically, HDAC2 inhibition reverses epigenetic silencing of p21 and restores tumor-suppressive chromatin states. Together, these results identify the HDAC2–H3K14ac axis as a therapeutic vulnerability in ESCC and provide preclinical support for romidepsin-based epigenetic intervention.

Genomics Proteomics & Bioinformatics
Tianjin Medical University Cancer Institute and Hospital (CN), Tianjin Medical University (CN)
Histone Deacetylase Inhibitors Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon